Knocking down breast cancer resistance protein (BCRP) by adenoviral vector-mediated rna interference (RNAI) in Sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of bcrp to drug biliary excretion

Molecular Pharmaceutics

Volumn 6, Issue 1, 2009, Pages 134-143

  Yue, Wei ^a,b   Abe, Koji ^a,b   Brouwer, Kim L R ^a  

^a University of North Carolina   (United States)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Biliary excretion; Breast cancer resistance protein (bcrp); Nitrofurantoin; Rna interference (rnai); Sandwich cultured hepatocytes

Indexed keywords

ADENOVIRUS VECTOR; BREAST CANCER RESISTANCE PROTEIN; DIGOXIN; ELACRIDAR; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; NITROFURANTOIN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1A1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCG2 PROTEIN, RAT; ACRIDINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BILE LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG TARGETING; IMMUNOBLOTTING; IN VITRO STUDY; KNOCKOUT GENE; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RNA INTERFERENCE; ADENOVIRUS; ANIMAL; DRUG EFFECT; GENE VECTOR; GENETICS; HEPATOBILIARY SYSTEM; METABOLISM; SECRETION; WISTAR RAT;

ACRIDINES; ADENOVIRIDAE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILIARY TRACT; CELLS, CULTURED; GENETIC VECTORS; MALE; NITROFURANTOIN; RATS; RATS, WISTAR; RNA INTERFERENCE; TETRAHYDROISOQUINOLINES;

EID: 62649119336     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp800100e     Document Type: Article

References (59)

1. Maliepaard, M.; Scheffer, G. L.; Faneyte, I. F.; van Gastelen, M. A.; Pijnenborg, A. C. L. M.; Schinkel, A. H.; van de Vijver, M. J.; Scheper, R. J.; Schellens, J. H. M. Subcellular Localization and Distribution of the Breast Cancer Resistance Protein Transporter in Normal Human Tissues. Cancer Res. 2001, 61, 3458-3464.
2. Choudhuri, S.; Klaassen, C. D. Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters. Int. J. Toxicol. 2006, 25, 231-259.
3. Sarkadi, B.; Homolya, L.; Szakacs, G.; Varadi, A. Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System. Physiol. Rev. 2006, 86, 1179-1236.
4. Imai, Y.; Nakane, M.; Kage, K.; Tsukahara, S.; Ishikawa, E.; Tsuruo, T.; Miki, Y.; Sugimoto, Y. C421A Polymorphism in the Human Breast Cancer Resistance Protein Gene Is Associated with Low Expression of Q141K Protein and Low-Level Drug Resistance. Mol. Cancer Ther. 2002, 1, 611-616.
5. Tamura, A.; Wakabayashi, K.; Onishi, Y.; Takeda, M.; Ikegami, Y.; Sawada, S.; Tsuji, M.; Matsuda, Y.; Ishikawa, T. Re- Evaluation and Functional Classification of Non-Synonymous Single Nucleotide Polymorphisms of the Human ATP-Binding Cassette Transporter ABCG2. Cancer Sci. 2007, 98, 231-239.
6. Sparreboom, A.; Gelderblom, H.; Marsh, S.; Ahluwalia, R.; Obach, R.; Principe, P.; Twelves, C.; Verweij, J.; McLeod, H. L. Diflomotecan Pharmacokinetics in Relation to ABCG2 421C>A Genotype. Clin. Pharmacol. Ther. 2004, 76, 38-44.
7. Sparreboom, A.; Loos, W. J.; Burger, H.; Sissung, T. M.; Verweij, J.; Figg, W. D.; Nooter, K.; Gelderblom, H. Effect of ABCG2 Genotype on the Oral Bioavailability of Topotecan. Cancer Biol. Ther. 2005, 4, 650-658.
8. Zhang, W.; Yu, B.-N.; He, Y.-J.; Fan, L.; Li, Q.; Liu, Z.-Q.; Wang, A.; Liu, Y.-L.; Tan, Z.-R.; Fen, J.; Huang, Y.-F.; Zhou, H.-H. Role of BCRP 421C > A Polymorphism on Rosuvastatin Pharmacokinetics in Healthy Chinese Males. Clin. Chim. Acta 2006, 575, 99-103.
9. Merino, G.; van Herwaarden, A. E.; Wagenaar, E.; Jonker, J. W.; Schinkel, A. H. Sex-Dependent Expression and Activity of the ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in Liver. Mol. Pharmacol. 2005, 67, 1765-1771.
10. Loos, W. J.; Gelderblom, H. J.; Verweij, J.; Brouwer, E.; de Jonge, M. J.; Sparreboom, A. Gender-Dependent Pharmacokinetics of Topotecan in Adult Patients. Anticancer Drugs 2000, 11, 673-680.
11. Hirano, M.; Maeda, K.; Matsushima, S.; Nozaki, Y.; Kusuhara, H.; Sugiyama, Y. Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin. Mol. Pharmacol. 2005, 68, 800-807.
12. Agarwal, S.; Pal, D.; Mitra, A. K. Both P-gp and MRP2 Mediate Transport of Lopinavir, a Protease Inhibitor. Int. J. Pharm. 2007, 339, 139-147.
13. Hardwick, L. J. A.; Velamakanni, S.; van Veen, H. W. The Emerging Pharmacotherapeutic Significance of the Breast Cancer Resistance Protein (ABCG2). Br. J. Pharmacol. 2007, 151, 163-174.
14. Allen, J. D.; Schinkel, A. H. Multidrug Resistance and Pharmacological Protection Mediated by the Breast Cancer Resistance Protein (BCRP/ABCG2). Mol. Cancer Ther. 2002, 1, 427-434.
15. de Bruin, M.; Miyake, K.; Litman, T.; Robey, R.; Bates, S. E. Reversal of Resistance by GF120918 in Cell Lines Expressing the ABC Half-Transporter, MXR. Cancer Lett. 1999, 146, 117-126.
16. van Loevezijn, A.; Allen, J. D.; Schinkel, A. H.; Koomen, G.-J. Inhibition of BCRP-Mediated Drug Efflux by Fumitremorgin-Type Indolyl Diketopiperazines. Bioorg. Med. Chem. Lett. 2001, 11, 29-32.
17. Evers, R.; Kool, M.; Smith, A. J.; van Deemter, L.; de Haas, M.; Borst, P. Inhibitory Effect of the Reversal Agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2- Mediated Transport. Br. J. Cancer 2000, 83, 366-374.
18. Zamek-Gliszczynski, M. J.; Nezasa, K. i.; Tian, X.; Kalvass, J. C.; Patel, N. J.; Raub, T. J.; Brouwer, K. L. R. The Important Role of Bcrp (Abcg2) in the Biliary Excretion of Sulfate and Glucuronide Metabolites of Acetaminophen, 4-Methylumbelliferone, and Harmol in Mice. Mol. Pharmacol. 2006, 70, 2127-2133.
19. Enokizono, J.; Kusuhara, H.; Sugiyama, Y. Effect of Breast Cancer Resistance Protein (Bcrp/Abcg2) on the Disposition of Phytoestrogens. Mol. Pharmacol. 2007, 72, 967-975.
20. LeCluyse, E. L.; Audus, K. L.; Hochman, J. H. Formation of Extensive Canalicular Networks by Rat Hepatocytes Cultured in Collagen-Sandwich Configuration. Am. J. Physiol. Cell Physiol. 1994, 266, C1764-C1774.
21. Liu, X.; LeCluyse, E. L.; Brouwer, K. R.; Gan, L. S.; Lemasters, J. J.; Stieger, B.; Meier, P. J.; Brouwer, K. L. R. Biliary Excretion in Primary Rat Hepatocytes Cultured in a Collagen-Sandwich Configuration. Am. J. Physiol. Gastrointest. Liver Physiol. 1999, 277, G12-G21.
22. Annaert, P. P.; Turncliff, R. Z.; Booth, C. L.; Thakker, D. R.; Brouwer, K. L. R. P-glycoprotein-mediated In Vitro Biliary Excretion in Sandwich-Cultured Rat Hepatocytes. Drug Metab. Dispos. 2001, 29, 1277-1283.
23. Tian, X.; Zamek-Gliszczynski, M. J.; Zhang, P.; Brouwer, K. L. R. Modulation of Multidrug Resistance-Associated Protein 2 (Mrp2) and Mrp3 Expression and Function with Small Interfering RNA in Sandwich-Cultured Rat Hepatocytes. Mol. Pharmacol. 2004, 66, 1004-1010.
24. El-Armouche, A.; Singh, J.; Naito, H.; Wittkopper, K.; Didie, M.; Laatsch, A.; Zimmermann, W.-H.; Eschenhagen, T. Adenovirus- Delivered Short Hairpin RNA Targeting PKC[alpha] Improves Contractile Function in Reconstituted Heart Tissue. J. Mol. Cell. Cardiol. 2007, 43, 371-376.
25. Herndon, C.; Fromm, L. Directing RNA Interference Specifically to Differentiated Muscle Cells. J. Muscle. Res. Cell Motil. 2007, 28, 11-17.
26. Merino, G.; Jonker, J. W.; Wagenaar, E.; van Herwaarden, A. E.; Schinkel, A. H. The Breast Cancer Resistance Protein (BCRP/ ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin. Mol. Pharmacol. 2005, 67, 1758-1764.
27. de Lannoy, I. A. M.; Silverman, M. The MDR1 Gene Product, P-glycoprotein, Mediates the Transport of the Cardiac Glycoside, Digoxin. Biochem. Biophys. Res. Commun. 1992, 189, 551-557.
28. Hunter, J.; Hirst, B. H.; Simmons, N. L. Drug Absorption Limited by P-Glycoprotein-Mediated Secretory Drug Transport in Human Intestinal Epithelial Caco-2 Cell Layers. Pharm. Res. 1993, 10, 743-749.
29. Liu, X.; Chism, J. P.; LeCluyse, E. L.; Brouwer, K. R.; Brouwer, K. L. R. Correlation of Biliary Excretion in Sandwich-Cultured Rat Hepatocytes and In Vivo in Rats. Drug Metab. Dispos. 1999, 27, 637-644.
30. Allen, J. D.; Brinkhuis, R. F.; Wijnholds, J.; Schinkel, A. H. The Mouse Bcrp1/Mxr/Abcp Gene: Amplification and Overexpression in Cell Lines Selected for Resistance to Topotecan, Mitoxantrone, or Doxorubicin. Cancer Res. 1999, 59, 4237-4241.
31. Seglen, P. O. Preparation of Isolated Rat Liver Cells. Methods Cell Biol. 1976, 13, 29-83.
32. Schinkel, A. H.; Wagenaar, E.; van Deemter, L.; Mol, C. A.; Borst, P. Absence of the mdr1a P-Glycoprotein in Mice Affects Tissue Distribution and Pharmacokinetics of Dexamethasone, Digoxin and Cyclosporin A. J. Clin. Invest. 1995, 96, 1698-1705.
33. Imai, Y.; Ishikawa, E.; Asada, S.; Sugimoto, Y. Estrogen-Mediated Post transcriptional Down-Regulation of Breast Cancer Resistance Protein/ABCG2. Cancer Res. 2005, 65, 596-604.
34. Aleman, C.; Annereau, J.-P.; Liang, X.-J.; Cardarelli, C. O.; Taylor, B.; Yin, J. J.; Aszalos, A.; Gottesman, M. M. P- glycoprotein, Expressed in Multidrug Resistant Cells, Is Not Responsible for Alterations in Membrane Fluidity or Membrane Potential. Cancer Res. 2003, 63, 3084-3091.
35. Muller, C.; Laurent, G.; Ling, V. P-Glycoprotein Stability is Affected by Serum Deprivation and High Cell Density in Multidrug-Resistant Cells. J. Cell. Physiol. 1995, 163, 538-544.
36. Jones, B. R.; Li, W.; Cao, J.; Hoffman, T. A.; Gerk, P. M.; Vore, M. The Role of Protein Synthesis and Degradation in the Post- Transcriptional Regulation of Rat Multidrug Resistance-Associated Protein 2 (Mrp2, Abcc2). Mol. Pharmacol. 2005, 68, 701-710.
37. Wang, W.; Soroka, C. J.; Mennone, A.; Rahner, C.; Harry, K.; Pypaert, M.; Boyer, J. L. Radixin Is Required to Maintain Apical Canalicular Membrane Structure and Function in Rat Hepatocytes. Gastroenterology 2006, 131, 878-884.
38. Muenster, U.; Grieshop, B.; Ickenroth, K.; Gnoth, M. Characterization of Substrates and Inhibitors for the In Vitro Assessment of Bcrp Mediated Drug-Drug Interactions. Pharm. Res. 2008, 25, 2320-2326.
39. Taipalensuu, J.; Tavelin, S.; Lazorova, L.; Svensson, A.-C.; Artursson, P. Exploring the Quantitative Relationship Between the Level of MDR1 Transcript, Protein and Function Using Digoxin as a Marker of MDR1-Dependent Drug Efflux Activity. Eur. J. Pharm. Sci. 2004, 21, 69-75.
40. Wang, Q.; Strab, R.; Kardos, P.; Ferguson, C.; Li, J.; Owen, A.; Hidalgo, I. J. Application and Limitation of Inhibitors in Drug- Transporter Interactions Studies. Int. J. Pharm. 2008, 356, 1218.
41. Henrich, C. J.; Bokesch, H. R.; Dean, M.; Bates, S. E.; Robey, R. W.; Goncharova, E. I.; Wilson, J. A.; McMahon, J. B. A High- Throughput Cell-Based Assay for Inhibitors of ABCG2 Activity. J. Biomol. Screening 2006, 11, 176-183.
42. Robey, R. W.; Honjo, Y.; van de Laar, A.; Miyake, K.; Regis, J. T.; Litman, T.; Bates, S. E. A Functional Assay for Detection of the Mitoxantrone Resistance Protein, MXR (ABCG2). Biochim. Biophys. Acta-Biomembranes 2001, 1512, 171-182.
43. Ozvegy, C.; Litman, T.; Szakács, G.; Nagy, Z.; Bates, S.; Varadi, A.; Sarkadi, B. Functional Characterization of the Human Mul- tidrug Transporter, ABCG2, Expressed in Insect Cells. Biochem. Biophys. Res. Commun. 2001, 285, 111-117.
44. Allen, J. D.; van Loevezijn, A.; Lakhai, J. M.; van der Valk, M.; van Tellingen, O.; Reid, G.; Schellens, J. H. M.; Koomen, G.-J.; Schinkel, A. H. Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter In Vitro and In Mouse Intestine by a Novel Analogue of Fumitremorgin C. Mol. Cancer Ther. 2002, 1, 417-425.
45. Hoffmaster, K.; Turncliff, R.; LeCluyse, E.; Kim, R.; Meier, P.; Brouwer, K. L. R. P-glycoprotein Expression, Localization, and Function in Sandwich-Cultured Primary Rat and Human Hepa- tocytes: Relevance to the Hepatobiliary Disposition of a Model Opioid Peptide. Pharm. Res. 2004, 21, 1294-1302.
46. Noe, B.; Hagenbuch, B.; Stieger, B.; Meier, P. J. Isolation of a Multispecific Organic Anion and Cardiac Glycoside Transporter From Rat Brain. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 10346-50.
47. Gerk, P. M.; Moscow, J. A.; McNamara, P. J. Basolateral Active Uptake of Nitrofurantoin in the CIT3 Cell Culture Model of Lactation. Drug Metab. Dispos. 2003, 31, 691-693.
48. Toddywalla, V. S.; Kari, F. W.; Neville, M. C. Active Transport of Nitrofurantoin Across a Mouse Mammary Epithelial Mono- layer. J. Pharmacol. Exp. Ther. 1997, 280, 669-676.
49. Ieiri, I.; Suwannakul, S.; Maeda, K.; Uchimaru, H.; Hashimoto, K.; Kimura, M.; Fujino, H.; Hirano, M.; Kusuhara, H.; Irie, S.; Higuchi, S.; Sugiyama, Y. SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers. Clin. Pharmacol. Ther. 2007, 82, 541-547.
50. Adkison, K. K.; Vaidya, S. S.; Lee, D. Y.; Koo, S. H.; Li, L.; Mehta, A. A.; Gross, A. S.; Polli, J. W.; Lou, Y.; Lee, E. J. The ABCG2 C421A Polymorphism Does not Affect Oral Nitrofurantoin Pharmacokinetics in Healthy Chinese Male Subjects. Br. J. Clin. Pharmacol. 2008, 66, 233-239.
51. Kelly, B. D.; Heneghan, M. A.; Bennani, F.; Connolly, C. E.; O'Gorman, T. A. Nitrofurantoin-Induced Hepatotoxicity Mediated by CD8+ T Cells. Am. J. Gastroenterol. 1998, 93, 819-821.
52. Reinhart, H. H.; Reinhart, E.; Korlipara, P.; Peleman, R. Combined Nitrofurantoin Toxicity to Liver and Lung. Gastroenterology 1992, 102, 1396-1399.
53. Boelsterli, U. A.; Ho, H. K.; Zhou, S.; Yeow Leow, K. Bioactivation and Hepatotoxicity of Nitroaromatic Drugs. Curr. Drug Metab. 2006, 7, 715-727.
54. Ghibellini, G.; Vasist, L. S.; Leslie, E. M.; Heizer, W. D.; Kowalsky, R. J.; Calvo, B. F.; Brouwer, K. L. R. In Vitro-In Vivo Correlation of Hepatobiliary Drug Clearance in Humans. Clin. Pharmacol. Ther. 2007, 81, 406-413.
55. Abe, K.; Bridges, A. S.; Brouwer, K. L. R. Use of Sandwich-Cultured Human Hepatocytes to Predict Biliary Clearance of Angiotensin II Receptor Blockers and HMG-CoA Reductase Inhibitors. Drug Metab. Dispos., in press.
56. Noe, J.; Portmann, R.; Brun, M.-E.; Funk, C. Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab. Dispos. 2007, 35, 1308-1314.
57. Seithel, A.; Eberl, S.; Singer, K.; Auge, D.; Heinkele, G.; Wolf, N. B.; Dorje, F.; Fromm, M. F.; Konig, J. The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3. Drug Metab. Dispos. 2007, 35, 779-786.
58. Poirier, A.; Funk, C.; Lavé, T.; Noe, J. New Strategies to Address Drug-Drug Interactions Involving OATPs. Curr. Opin. Drug Discovery Dev. 2007, 10, 74-83.
59. Roche Pharmaceuticals. Cellcept package insert Nutley, NJ, May 2008; p 20.